OBJECTIVES: To assess the risk of death in relation to apolipoprotein E (APOE) genotype and to evaluate how APOE genotype interacts with dementia and with other major medical conditions to affect survival. DESIGN: A 6-year prospective cohort study of dementia, APOE genotype and survival. SETTING: Health maintenance organization in southern California. PARTICIPANTS: One thousand eight hundred forty-two white women aged 75 and older. MEASUREMENTS: Dementia was determined using a multistage assessment procedure, medical record, and death certificate review. RESULTS: With women with the APOE 3/3 genotype as the referent, age-adjusted hazard ratios (HRs) for death according to genotype were 1.25 (95% confidence interval (CI)=1.00-1.56) for APOE 2/4, 3/4, or 4/4 and 0.83 (95% CI=0.62-1.13) for APOE 2/3 or 2/2. Survival was associated with APOE genotype (log rank test P=.02). Women with the APOE 2/4, 3/4, or 4/4 genotype died at an earlier age, and those with APOE 2/2 or 2/3 died later than those with the APOE 3/3 genotype. After adjustment for age, education, and hormone use, HRs for death were significantly higher in women with the APOE 2/4, 3/4, or 4/4 genotype who developed dementia (HR=3.74; 95% CI=2.81-4.99) and the APOE 2/3 genotype (HR=3.23; 95%=CI=1.97-5.28) than in women without dementia and the APOE 3/3 genotype. The HRs for death were greater with other medical conditions, but no interaction with any APOE genotype was found. CONCLUSION: In this population of elderly women, although having at least one epsilon4 allele increased the chances of an earlier death, having dementia increased the risk of death regardless of APOE genotype.
OBJECTIVES: To assess the risk of death in relation to apolipoprotein E (APOE) genotype and to evaluate how APOE genotype interacts with dementia and with other major medical conditions to affect survival. DESIGN: A 6-year prospective cohort study of dementia, APOE genotype and survival. SETTING: Health maintenance organization in southern California. PARTICIPANTS: One thousand eight hundred forty-two white women aged 75 and older. MEASUREMENTS: Dementia was determined using a multistage assessment procedure, medical record, and death certificate review. RESULTS: With women with the APOE 3/3 genotype as the referent, age-adjusted hazard ratios (HRs) for death according to genotype were 1.25 (95% confidence interval (CI)=1.00-1.56) for APOE 2/4, 3/4, or 4/4 and 0.83 (95% CI=0.62-1.13) for APOE 2/3 or 2/2. Survival was associated with APOE genotype (log rank test P=.02). Women with the APOE 2/4, 3/4, or 4/4 genotype died at an earlier age, and those with APOE 2/2 or 2/3 died later than those with the APOE 3/3 genotype. After adjustment for age, education, and hormone use, HRs for death were significantly higher in women with the APOE 2/4, 3/4, or 4/4 genotype who developed dementia (HR=3.74; 95% CI=2.81-4.99) and the APOE 2/3 genotype (HR=3.23; 95%=CI=1.97-5.28) than in women without dementia and the APOE 3/3 genotype. The HRs for death were greater with other medical conditions, but no interaction with any APOE genotype was found. CONCLUSION: In this population of elderly women, although having at least one epsilon4 allele increased the chances of an earlier death, having dementia increased the risk of death regardless of APOE genotype.
Authors: Maria G Matera; Daniele Sancarlo; Francesco Panza; Carolina Gravina; Grazia D'Onofrio; Vincenza Frisardi; Grazia Longo; Luigi P D'Ambrosio; Filomena Addante; Massimiliano Copetti; Vincenzo Solfrizzi; Davide Seripa; Alberto Pilotto Journal: Age (Dordr) Date: 2010-04-20
Authors: Konstantin G Arbeev; Svetlana V Ukraintseva; Liubov S Arbeeva; Igor Akushevich; Alexander M Kulminski; Anatoliy I Yashin Journal: Biogerontology Date: 2010-12-31 Impact factor: 4.277
Authors: Alexander M Kulminski; Irina Culminskaya; Svetlana V Ukraintseva; Konstantin G Arbeev; Liubov Arbeeva; Deqing Wu; Igor Akushevich; Kenneth C Land; Anatoli I Yashin Journal: Aging Cell Date: 2011-04-07 Impact factor: 9.304
Authors: Emily G Jacobs; Candyce Kroenke; Jue Lin; Elissa S Epel; Heather A Kenna; Elizabeth H Blackburn; Natalie L Rasgon Journal: PLoS One Date: 2013-02-13 Impact factor: 3.240
Authors: Carolyn M Rutter; Ifeanyi Edochie; Esther M Friedman; Mary E Slaughter; Margaret M Weden Journal: Med Decis Making Date: 2021-06-14 Impact factor: 2.583
Authors: Konstantin G Arbeev; Svetlana V Ukraintseva; Alexander M Kulminski; Igor Akushevich; Liubov S Arbeeva; Irina V Culminskaya; Deqing Wu; Anatoliy I Yashin Journal: Scientifica (Cairo) Date: 2012
Authors: Alexander M Kulminski; Konstantin G Arbeev; Irina Culminskaya; Liubov Arbeeva; Svetlana V Ukraintseva; Eric Stallard; Kaare Christensen; Nicole Schupf; Michael A Province; Anatoli I Yashin Journal: PLoS Genet Date: 2014-01-30 Impact factor: 5.917
Authors: Sujuan Gao; Yinlong Jin; Frederick W Unverzagt; Yibin Cheng; Liqin Su; Chenkun Wang; Feng Ma; Ann M Hake; Carla Kettler; Chen Chen; Jingyi Liu; Jianchao Bian; Ping Li; Jill R Murrell; Daniel O Clark; Hugh C Hendrie Journal: Arch Public Health Date: 2014-03-26